Middle East, North Africa, Afghanistan & Pakistan vs Rwanda: Immunization, Hib3
Immunization, Hib3 over time
- Middle East, North Africa, Afghanistan & Pakistan
- Rwanda
How they compare
Rwanda currently reports 98.0% against 84.5% in Middle East, North Africa, Afghanistan & Pakistan, a difference of 13.5%.
That makes Rwanda's figure about 1.2 times Middle East, North Africa, Afghanistan & Pakistan's.
Across all 23 years both countries report, Rwanda has been ahead every year.
Middle East, North Africa, Afghanistan & Pakistan ranks 19th and Rwanda ranks 20th of 43 groups.
Rwanda has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Middle East, North Africa, Afghanistan & Pakistan | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 18.8% | 94.8% | 76.0% | Rwanda |
| 2010s | 69.8% | 97.7% | 27.9% | Rwanda |
| 2020s | 83.4% | 93.8% | 10.4% | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Middle East, North Africa, Afghanistan & Pakistan or Rwanda?
- Rwanda, at 98.0% against 84.5% in Middle East, North Africa, Afghanistan & Pakistan as of 2024.
- What is the difference in immunization, hib3 between Middle East, North Africa, Afghanistan & Pakistan and Rwanda?
- 13.5%, with Rwanda ahead.
- How many years of comparable data are there for Middle East, North Africa, Afghanistan & Pakistan and Rwanda?
- 23 years are reported by both, from 2002 to 2024.
- How do Middle East, North Africa, Afghanistan & Pakistan and Rwanda rank globally for immunization, hib3?
- Middle East, North Africa, Afghanistan & Pakistan ranks 19th and Rwanda ranks 20th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.